Abstract
Dual antiplatelet therapy (DAPT) is a key component of therapy for acute coronary syndromes managed with and without percutaneous coronary intervention. Recent advances have given patients a wider variety of therapeutic options including the use of combinations of agents, dosing strategies, and durations of therapy. The optimal regimen minimizes thrombotic risk without increasing the risk of bleeding. Choosing the best therapy for each patient is an individualized dilemma that requires new, evidence-based tools to support regimen decision-making.
| Original language | English |
|---|---|
| Article number | 405 |
| Journal | Current Cardiology Reports |
| Volume | 15 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2013 |
Keywords
- Acute coronary syndromes
- Bleeding
- Clinical prediction tool
- Clopidogrel
- Cost-effectiveness
- Dual antiplatelet therapy
- Ischemia
- Platelet function testing
- Prasugrel
- Therapeutic window
- Ticagrelor
Fingerprint
Dive into the research topics of 'Dual antiplatelet therapy dilemmas: Duration and choice of antiplatelets in acute coronary syndromes topical collection on management of acute coronary syndromes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver